The Role of Universities in Accelerating Bioscience Research

Session Overview & Objectives

• Moderator Steve Mayo (Caltech Division Chair) outlined three focal points:
  • Universities as venues for new bioscience approaches via biological engineering.
  • The university role in patient-oriented activities, specifically clinical trials and technology transfer.
  • Future challenges, including the impact of funding sequestration on U.S. bioscience.
• Panelists include Nobel Laureate David Baltimore (Caltech), Joel Burdick (Caltech), James Economou (UCLA), Michael Quick (USC), and Owen Witte (UCLA).

Biological Engineering & "Engineering Immunity" (Caltech/UCLA Collaboration)

• David Baltimore defined biological engineering as using biology (molecules, cells, tissues) as a substrate rather than physical materials like silicon.
• The "Engineered Immunity" project aims to turn muscle cells into antibody-producing organs to prevent HIV infection by bypassing the native immune system.
• Methodology involves using adeno-associated viruses (AAV) as vectors to insert antibody-producing genes into muscle DNA, effectively "turning viruses against viruses."
• The consortium (Caltech, UCLA, USC) has progressed from conceptual work to clinical trials treating cancer (melanoma) using engineered T-lymphocytes.
• Current clinical data includes 14–15 patients treated, a result achieved within seven years of establishing the academic consortium.
• Owen Witte noted a shift in academic culture allowing researchers to prove therapeutic concepts in humans within academic settings rather than handing off prematurely to industry.

USC & UCLA Strategies for Interdisciplinary Integration

• USC launched the Health Technology and Engineering (HTE) program to bridge the gap between engineering PhDs and MD students.
  • Structure involves 6–12 months of joint clinical rounds and laboratory work, creating engineers versed in medicine and physicians versed in engineering.
• Michael Quick emphasized physical integration (e.g., shared buildings, coffee machines) and problem-based framing (solving specific diseases like HIV) over discipline-based silos.
• Joint MD-PhD programs exist between Caltech/UCLA and Caltech/USC to foster continuous interaction between basic science and clinical care.

Funding Mechanisms for Translational Research

• Standard NIH R01 grants are often insufficient for early-stage human trials; the panel relies on programmatic grants (PO1), private foundations, and philanthropic support.
• The California Institute for Regenerative Medicine recently provided ~$20 million over five years to fund clinical trial conduct and GMP manufacturing for engineered immunity therapies.
• Francis Collins (NIH) noted that NIH funding remains roughly 53% basic and 47% clinical, with the R01 remaining the primary mechanism despite a rise in cooperative agreements for team science.
• Funding access remains difficult due to sequestration; no single mechanism currently solves the "valley of death" without team-based, multi-source funding strategies.

Tech Transfer, Entrepreneurship, and Industry Partnerships

• Joel Burdick reported that large medical device companies are increasingly unwilling to fund high-risk early-stage trials, often offering only to acquire successful startups later.
• In response, academics are forced to become entrepreneurs, forming their own companies (e.g., spinal cord injury devices) funded by foundations and NIH U01 grants.
• James Economou highlighted the need for academic institutions to build "research engines" (clinical translational science institutes) and integrated IRBs to accelerate multi-site trials.
• UCLA is creating an entrepreneurial ecosystem with business advisory boards, incubators, and proof-of-concept grants to mature discoveries before licensing.
• Industry representative Remy (Sanofi) suggested optimal partnerships involve early-stage disruptive science support, shared risk, and integrated spaces (e.g., medical schools + engineering) for rapid proof-of-concept in humans.

Investment & Capital Ecosystem Challenges

• Joe Boistak (Brightwater's Capital) identified the lack of accessible capital as the primary bottleneck, noting a rupture in the VC community and the need for pooled assets rather than single-molecule bets.
• Boistak proposed creating themed pools (e.g., pancreatic cancer platforms with diagnostics and therapeutics) to layer risk and attract institutional investment.
• David Baltimore countered that aggregation risks diluting focus, arguing investors require clear paths to profit and defined risk profiles for specific assets.
• Panelists agreed that corporate venturing (e.g., Pfizer's Center for Therapeutic Innovation) may be more effective than traditional VC for bridging early-stage gaps.

Conflict of Interest & Regulatory Environment

• Francis Collins raised concerns regarding new NIH financial conflict of interest (COI) guidelines, asking if they have hindered university-industry collaboration.
• James Economou (UCLA) stated that COI committees have shifted from enforcement to a "concierge service" model, actively helping faculty manage disclosures to facilitate partnerships while maintaining compliance.
• Panel consensus suggests that while compliance costs have risen, the new regulations have not significantly impeded the ability of universities to engage with industry or the flow of innovation.
• Discussion on Bayh-Dole and the Stanford v. Roche ruling was deferred due to time constraints; panelists noted the "first-to-file" patent law change had minimal impact on Caltech's patenting activity.

Forward-Looking Statements & Strategic Recommendations

• CEO Partnerships: David Baltimore emphasized that scientists must partner with professional CEOs to navigate fundraising and management, as scientists should not focus solely on capital acquisition.
• Angel Funding Gap: Investors noted a "zero-stage" gap where early funding ($50k–$500k) is too small for institutional investors but too large for individual angels, creating a bottleneck.
• Future of Trials: The panel anticipates continued reliance on academic-led clinical trials for proof-of-concept, necessitating new funding structures that mimic mutual funds or ETFs for therapeutic pools.
• Cultural Shift: Academic reward systems and departmental structures (19th-century models) must evolve to recognize and incentivize team science and entrepreneurship.